BPTES

BPTES is an allosteric and selective glutaminase inhibitor with an IC50 of 0.16 μM.

Product Specifications

CAS Number

[314045-39-1]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Glutaminase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BPTES.html

Purity

98.75

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(NC1=NN=C(CCSCCC2=NN=C(NC(CC3=CC=CC=C3)=O)S2)S1)CC4=CC=CC=C4

Molecular Formula

C24H24N6O2S3

Molecular Weight

524.68

Precautions

H315, H319, H335

References & Citations

[1]Elgogary A, et al. Combination therapy with BPTES nanoparticles and targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A. 2016 Sep 6;113 (36) :E5328-36.|[2]Meghan J. Seltzer, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010 Nov 15; 70 (22) : 8981-8987.|[3]Lee JS, et al. Glutaminase 1 inhibition reduces thymidine synthesis in NSCLC. Biochem Biophys Res Commun. 2016 Aug 26;477 (3) :374-82|[4]Lee JS, et al. Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC. Cell Death Dis. 2016 Dec 8;7 (12) :e2511.